drugset
drugset / Trial / NCT05188469

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

NCT05188469 ↗

Phase 1/2 Completed 67 enrolled EyeGene Inc. Novotech (Australia) Pty Limited · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

This is Phase 1 and 2a, Multi-center, Open-label study designed to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo vaccine in Healthy Adult Volunteers

Timeline

Start
2022-03-22
Primary completion
2024-05-29
Completion
2025-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject EG-COVARo Messenger RNA (mRNA) 800 ug Intramuscular
Subject EG-COVID Messenger RNA (mRNA) 400 ug Intramuscular
Subject EG-COVID Messenger RNA (mRNA) 800 ug Intramuscular
Subject EG-COVID-001 Messenger RNA (mRNA) 200 ug Intramuscular
Subject EG-COVID-003 Messenger RNA (mRNA) 100 ug Intramuscular

Indications

No indication recorded.